Research

Macro partitioning

Myostatin-activin pathway inhibitors (MAPi), specifically bimagrumab, can reduce fat mass while preserving or increasing lean mass, offering a potential solution to the lean mass loss associated with GLP-1 agonists.

If you are concerned about losing muscle on weight loss drugs, ask your doctor about Myostatin-Activin Pathway Inhibitors (MAPi) like bimagrumab. In studies, this drug helped patients lose fat while actually gaining muscle. It is currently being studied in combination with GLP-1 drugs.

ModerateSupportsMEDIUM confidence
Bimagrumab binds and blocks the activin type II receptor... has been shown to reduce fat mass while preserving or increasing lean mass. ... For those receiving bimagrumab, there were significant decreases in fat mass (− 20.5%) compared to placebo (− 0.5%) and increase in lean mass (+ 3.6%) compared to placebo (− 0.8%).
Donna H. Ryan · Reviews in Endocrine and Metabolic Disorders · 2025

Why this rating

Based on a Phase 2 study (n=77) in T2D patients; results are promising but from a smaller, specific population and not yet published for obesity combinations.

Source

New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?

Donna H. Ryan · Reviews in Endocrine and Metabolic Disorders · 2025

DOI 10.1007/s11154-025-09967-4

narrative_reviewCited 22×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →